Differences in clinical outcomes of COVID-19 among vaccinated and unvaccinated kidney transplant recipients.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
26 05 2022
Historique:
received: 12 12 2021
revised: 07 04 2022
accepted: 20 04 2022
pubmed: 4 5 2022
medline: 20 5 2022
entrez: 3 5 2022
Statut: ppublish

Résumé

The remarkable efficacy and effectiveness of COVID-19 vaccines have been described in healthy individuals, but kidney transplant recipients have been excluded from these studies. Therefore, real-world evidence of these vaccines can guide clinicians in predicting complications in kidney transplant recipients and how many doses of vaccines are protective. In this study, we aimed to investigate the impact of the COVID-19 vaccines on kidney transplant recipients with SARS-CoV-2 infection. This matched case-control study included vaccinated kidney transplant recipients with COVID-19 from two centers between 1 May and 1 October 2021. All patients in the vaccinated group received a minimum of two doses of the vaccine and were diagnosed with COVID-19 at least one month after the last dose. Each vaccinated patient was matched with an unvaccinated kidney transplant recipient diagnosed with COVID. The endpoints were all-cause mortality, hospitalization, intensive care unit admission, acute kidney injury, cytokine storm, and acute respiratory distress syndrome. The median age of vaccinated seventy-two participants was 45 years, and 41 of the participants were men in the vaccinated group. Four patients in the vaccinated group and nine patients in the control group died during follow-up (p = 0.247). Seventeen patients in the vaccinated group, thirty-four participants in the control group were hospitalized (p = 0.004); five vaccinated patients and ten unvaccinated patients were followed-up in the ICU during follow-up (p = 0.168). Thirteen of the vaccinated and twelve unvaccinated patients developed acute kidney injury (p = 0.16). The occurrence of cytokine storm (n = 4 vs. n = 11; p = 0.061) and acute respiratory distress syndrome (n = 5 vs. n = 10; p = 0.168) was higher in the patient group compared to the control group. COVID-19 remains a fatal disease despite advancing treatment modalities and preventive strategies. COVID-19 vaccines can't prevent death in all kidney transplant recipients, but they decrease hospitalization rate and duration in most patients.

Identifiants

pubmed: 35504784
pii: S0264-410X(22)00519-9
doi: 10.1016/j.vaccine.2022.04.066
pmc: PMC9042733
pii:
doi:

Substances chimiques

COVID-19 Vaccines 0
Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3313-3319

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Transplantation. 2021 Nov 1;105(11):e263-e264
pubmed: 34310530
Transplantation. 2022 May 1;106(5):1012-1023
pubmed: 35320154
Nephrol Dial Transplant. 2020 Nov 1;35(11):1973-1983
pubmed: 33151337
JAMA Netw Open. 2021 Nov 1;4(11):e2136030
pubmed: 34817587
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Am J Transplant. 2020 Nov;20(11):3182-3190
pubmed: 32654422
Transpl Infect Dis. 2021 Dec;23(6):e13740
pubmed: 34606134
Transplantation. 2021 Oct 1;105(10):2170-2174
pubmed: 33859151
BMJ. 2021 May 13;373:n1088
pubmed: 33985964
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
JAMA. 2021 Jun 1;325(21):2204-2206
pubmed: 33950155
Clin Kidney J. 2021 Dec 27;15(3):527-533
pubmed: 35198159
N Engl J Med. 2021 Sep 2;385(10):875-884
pubmed: 34233097
EBioMedicine. 2022 Mar;77:103904
pubmed: 35248996
MMWR Morb Mortal Wkly Rep. 2021 Mar 19;70(11):396-401
pubmed: 33735160

Auteurs

Erol Demir (E)

Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. Electronic address: eroldemir83@yahoo.com.

Hamad Dheir (H)

Division of Nephrology, Department of Internal Medicine, Sakarya University Training and Research Hospital, Sakarya, Turkey. Electronic address: hamaddheir@gmail.com.

Seda Safak (S)

Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. Electronic address: sedasafak_24@hotmail.com.

Ayse Serra Artan (A)

Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. Electronic address: ayseserra@gmail.com.

Savas Sipahi (S)

Division of Nephrology, Department of Internal Medicine, Sakarya University Training and Research Hospital, Sakarya, Turkey. Electronic address: ssipahi@sakarya.edu.tr.

Aydin Turkmen (A)

Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. Electronic address: turkmenaydin@yahoo.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH